Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Liver Transpl ; 28(8): 1321-1331, 2022 08.
Article in English | MEDLINE | ID: mdl-35332652

ABSTRACT

Cardiovascular disease (CVD) significantly contributes to morbidity and mortality after liver transplantation (LT). Cirrhotic cardiomyopathy (CCM) is a risk factor for CVD after transplant. CCM criteria were originally introduced in 2005 with a revision proposed in 2020 reflecting echocardiographic technology advancements. This study assesses the two criteria sets in predicting major adverse cardiac events (MACE) after transplant. This single-center retrospective study reviewed adult LT recipients between January 1, 2009, and December 31, 2018. Patients with insufficient pre-LT echocardiographic data, prior ischemic heart disease, portopulmonary hypertension, or longitudinal care elsewhere were excluded. The primary composite outcome was MACE (arrhythmia, heart failure, cardiac arrest, and/or cardiac death) after transplant. Of 1165 patients, 210 met the eligibility criteria. CCM was present in 162 patients (77%) per the original criteria and 64 patients (30%) per the revised criteria. There were 44 MACE and 31 deaths in the study period. Of the deaths, 38.7% occurred secondary to CVD. CCM defined by the original criteria was not associated with MACE after LT (p = 0.21), but the revised definition was significantly associated with MACE (hazard ratio [HR], 1.93; 95% confidence interval, 1.05-3.56; p = 0.04) on multivariable analysis. Echocardiographic variable analysis demonstrated low septal e' as the most predictive variable for MACE after LT (HR, 3.45; p < 0.001). CCM, only when defined by the revised criteria, was associated with increased risk for MACE after LT, validating the recently revised CCM definition. Abnormal septal e', reflecting impaired relaxation, appears to be the most predictive echocardiographic criterion for MACE after LT.


Subject(s)
Cardiomyopathies , Cardiovascular Diseases , Liver Transplantation , Adult , Cardiomyopathies/complications , Cardiomyopathies/etiology , Cardiovascular Diseases/etiology , Humans , Liver Cirrhosis/complications , Liver Cirrhosis/diagnosis , Liver Cirrhosis/surgery , Liver Transplantation/adverse effects , Retrospective Studies , Risk Factors
2.
BMC Nephrol ; 20(1): 373, 2019 10 17.
Article in English | MEDLINE | ID: mdl-31623566

ABSTRACT

BACKGROUND: Medication non-adherence is a risk factor for acute kidney transplant rejection. The association of non-adherence with short-term allograft loss in patients who develop acute rejection and are subsequently treated with maximal therapy is unknown. METHODS: We conducted a retrospective single center cohort study of adult patients who developed acute rejection from January 2003 to December 2017 and were treated with lymphocyte depletion. Clinicopathologic characteristics including adherence status were collected and descriptive statistics utilized to compare groups. The primary outcome was all-cause graft loss at 6 months after acute rejection treatment. A multivariable logistic regression quantified the association of non-adherence with the outcome. RESULTS: A total of 182 patients were included in the cohort, of whom 71 (39%) were non-adherent. Compared to adherent patients, non-adherent patients were younger (mean age 37y vs 42y), more likely to be female (51% vs 35%) and developed acute rejection later (median 2.3y vs 0.5y from transplant). There were no differences in estimated glomerular filtration rate or need for dialysis on presentation, Banff grade, or presence of antibody mediated rejection between the 2 groups. Overall, 48 (26%) patients lost their grafts at 6 months after acute rejection treatment. In adjusted analysis, non-adherence was associated with all-cause graft loss at 6 months after acute rejection treatment [OR 2.64 (95% CI 1.23-5.65, p = 0.012]. CONCLUSIONS: After adjusting for common confounders, non-adherent patients were at increased risk for short-term allograft loss after a severe acute rejection despite lymphocyte depletion. This finding may aid clinicians in risk stratifying patients for poor short-term outcomes and treatment futility.


Subject(s)
Graft Rejection/drug therapy , Graft Survival , Immunosuppressive Agents/therapeutic use , Medication Adherence , Acute Disease , Adult , Age Factors , Alemtuzumab/therapeutic use , Allografts , Antilymphocyte Serum/therapeutic use , Female , Graft Rejection/therapy , Humans , Kidney Transplantation , Lymphocyte Depletion , Male , Middle Aged , Muromonab-CD3/therapeutic use , Proportional Hazards Models , Retrospective Studies , Risk Factors , Sex Factors , Time Factors , Young Adult
3.
ACG Case Rep J ; 9(6): e00800, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35756725

ABSTRACT

Sarcoidosis is a systemic disease characterized by noncaseating granulomatous inflammation. Gastrointestinal involvement in sarcoidosis is a very rare occurrence, with the colon being affected in few patients. We present a case of sarcoidosis presenting as multiple colonic polyps found on routine colorectal cancer screening colonoscopy. Histopathology of the polyps showed noncaseating granulomas.

SELECTION OF CITATIONS
SEARCH DETAIL